Skip to content
Evofem Biosciences, Inc.
About Us
Mission
Management
Board of Directors
Saundra Pelletier
KIM P. KAMDAR, Ph.D.
Tony O’Brien
Lisa Rarick, MD, FACOG
Colin Rutherford
Our Product
phexxi
®
Publications
Investors
Investor Overview
Events & Presentations
Press Releases
Stock Information
Financial Information
SEC Filings
Analyst Coverage
Corporate Governance
Committee Composition
Board of Directors
Charters + Code of Ethics
Investor Resources
Investor Contact
Investor FAQs
Contact
Investor Contact
Media Contact
General Contact
Careers
Pregnancy Intendedness with Vaginal PH Modulator: Results from the Phase 3 Ampower Trial
Post navigation
Previous:
Compliance with Vaginal PH Modulator in the Phase 3 Ampower Contraceptive Trial
Next:
EVO100 Prevents Chlamydia and Gonorrhea in Women at High-Risk for Infection
Back
to
Top
